중동 및 아프리카 상처 치료 생물학 시장 – 2028년까지의 산업 동향 및 예측

TABLE OF CONTENTS MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED
2.2 GEOGRAPHIC SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 RESEARCH METHODOLOGY
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.1 DBMR MARKET POSITION GRID
2.2 DBMR MARKET CHALLENGE MATRIX
2.3 SECONDARY SOURCES
2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.1.1 INCREASING CASES OF DIABETIC FOOT ULCERS
3.1.2 INCREASING INCIDENCES OF BURN CASES
3.1.3 RISING NUMBER OF GERIATRIC POPULATION
3.1.4 INNOVATION IN WOUND CARE BIOLOGICS
3.1.5 NEW PRODUCT LAUNCHES

3.2 RESTRAINS

3.2.1 HIGH COST OF WOUND TREATMENT AND WOUND CARE BIOLOGICS
3.2.2 RISK OF SKIN SUBSTITUE FAILURE

3.3 OPPORTUNITIES

3.3.1 3D SKIN PRINTING
3.3.2 AWARENESS PROGRAMS

3.4 CHALLENGES

3.4.1 LACK OF WOUND MANAGEMENT SERVICES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET, BY PRODUCT TYPE

6.1 OVERVIEW

6.2 SYNTHETIC SKIN GRAFTS

6.3 GROWTH FACTORS

6.3.1 PLATELET DERIVED GROWTH FACTOR (PDGF)
6.3.2 PLATELET RICH PLASMA (PRP)
6.3.3 EPIDERMAL GROWTH FACTORS (EGF)
6.3.4 BASIC FIBROBLAST GROWTH FACTORS (BFGF)
6.3.5 GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF)
6.3.6 TALACTOFERRIN ALFA
6.3.7 THROMBIN PEPTIDE
6.3.8 KERATINOCY GROWTH FACTOR (KGF)

6.4 ALLOGRAFTS

6.5 XENOGRAFTS

7 MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE

7.1 OVERVIEW

7.2 WOUNDS

7.2.1 SURGICAL WOUND

7.2.1.1 SKIN SURGERY

7.2.1.1.1 WOUND CLOSURE
7.2.1.1.2 SKIN BIOPSY
7.2.1.1.3 SKIN FLAP
7.2.1.1.4 SKIN GRAFT
7.2.1.1.5 OTHERS

7.2.1.2 COSMETIC PROCEDURE

7.2.1.2.1 BREST ENHANCEMENT
7.2.1.2.2 FACIAL CONTOURING
7.2.1.2.3 FACIAL REJUVENATION:
7.2.1.2.4 BODY CONTOURING
7.2.1.2.5 SKIN REJUVENATION
7.2.1.2.6 OTHERS

7.2.1.3 GYNECOLOGIC PROCEDURES

7.2.1.3.1 PUBOVAGINALIS SLING
7.2.1.3.2 PELVIC FLOOR RECONSTRUCTION
7.2.1.3.3 RECTOCELE REPAIR SURGERY
7.2.1.3.4 OTHERS

7.2.1.4 GASTROINTESTINAL PROCEDURE

7.2.1.4.1 GENERAL GASTROINTESTINAL SURGERY
7.2.1.4.2 HERNIA
7.2.1.4.3 OTHERS

7.2.2 ACUTE WOUNDS

7.2.3 CHRONIC WOUNDS

7.2.4 TRAUMATIC WOUNDS

7.3 BURNS

7.3.1 ULCERS
7.3.2 DIABETIC ULCERS
7.3.3 PRESSURE ULCER
7.3.4 VENOUS ULCER
7.3.5 OTHERS

8 MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET, BY END USER

8.1 OVERVIEW
8.2 HOSPITALS
8.3 WOUND CARE CENTERS
8.4 AMBULATORY SURGICAL CENTERS
8.5 CLINICS
8.6 COMMUNITY HEALTHCARE CENTER

9 MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET: GEOGRAPHY

9.1 MIDDLE EAST & AFRICA

9.1.1 SOUTH AFRICA
9.1.2 REST OF MIDDLE EAST & AFRICA

10 MIDDLE EAST & AFRICA WOUND CARE BIOLOGICS MARKET, COMPANY LANDSCAPE

10.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

11 COMPANY PROFILE

11.1 MIMEDX.

11.1.1 COMPANY OVERVIEW
11.1.2 REVENUE ANALYSIS:
11.1.3 COMPANY SHARE ANALYSIS:
11.1.4 PRODUCT PORTFOLIO
11.1.5 RECENT DEVELOPMENTS

11.2 ORGANOGENESIS INC

11.2.1 COMPANY OVERVIEW
11.2.2 GEOGRAPHIC PRESENCE
11.2.3 COMPANY SHARE ANALYSIS:
11.2.4 PRODUCT PORTFOLIO
11.2.5 RECENT DEVELOPMENTS

11.3 INTEGRA LIFESCIENCES

11.3.1 COMPANY OVERVIEW
11.3.2 REVENUE ANALYSIS
11.3.3 COMPANY SHARE ANALYSIS:
11.3.4 PRODUCT PORTFOLIO
11.3.5 RECENT DEVELOPMENTS

11.4 CONVATEC INC.

11.4.1 COMPANY OVERVIEW
11.4.2 REVENUE ANALYSIS
11.4.3 COMPANY SHARE ANALYSIS:
11.4.4 PRODUCT PORTFOLIO :
11.4.5 RECENT DEVELOPMENTS

11.5 ACELL INC.

11.5.1 COMPANY OVERVIEW
11.5.2 PRODUCT PORTFOLIO
11.5.3 RECENT DEVELOPMENTS

11.6 ALLOSOURCE

11.6.1 COMPANY OVERVIEW
11.6.2 PRODUCT PORTFOLIO
11.6.3 RECENT DEVELOPMENTS

11.7 ALPHATEC SPINE, INC. ( A SUBSIDARY OF ALPHATEC HOLDINGS, INC)

11.7.1 COMPANY OVERVIEW
11.7.2 PRODUCT PORTFOLIO
11.7.3 RECENT DEVELOPMENTS

11.8 AMNIO TECHNOLOGY, LLC

11.8.1 COMPANY OVERVIEW
11.8.2 PRODUCT PORTFOLIO
11.8.3 RECENT DEVELOPMENTS

11.9 AMNIOX MEDICAL, INC.

11.9.1 COMPANY OVERVIEW
11.9.2 PRODUCT PORTFOLIO
11.9.3 RECENT DEVELOPMENTS

11.10 ANIKA THERAPEUTICS, INC.

11.10.1 COMPANY OVERVIEW
11.10.2 REVENUE ANALYSIS
11.10.3 PRODUCT PORTFOLIO
11.10.4 RECENT DEVELOPMENTS

11.11 BIOHORIZONS IPH, INC ( A SUBSIDARY OF HENRY SCHEIN, INC.)

11.11.1 COMPANY OVERVIEW
11.11.2 GEOGRAPHICPRESENCE
11.11.3 PRODUCT PORTFOLIO
11.11.4 RECENT DEVELOPMENTS

11.12 KERECIS

11.12.1 COMPANY OVERVIEW
11.12.2 GEOGRAPHICAL PRESENCE
11.12.3 PRODUCT PORTFOLIO
11.12.4 RECENT DEVELOPMENTS

11.13 MARINE POLYMER TECHNOLOGIES, INC

11.13.1 COMPANY OVERVIEW
11.13.2 PRODUCT PORTFOLIO
11.13.3 RECENT DEVELOPMENTS

11.14 MÖLNLYCKE HEALTH CARE AB

11.14.1 COMPANY OVERVIEW
11.14.2 REVENUE ANALYSIS
11.14.3 PRODUCT PORTFOLIO
11.14.4 RECENT DEVELOPMENTS

11.15 OSIRIS THERAPEUTICS, INC.

11.15.1 COMPANY OVERVIEW
11.15.2 REVENUE ANALYSIS
11.15.3 PRODUCT PORTFOLIO
11.15.4 RECENT DEVELOPMENTS

11.16 SKYE BIOLOGICS INC.

11.16.1 COMPANY OVERVIEW
11.16.2 PRODUCT PORTFOLIO :
11.16.3 RECENT DEVELOPMENT:

11.17 SMITH AND NEPHEW

11.17.1 COMPANY OVERVIEW
11.17.2 REVENUE ANALYSIS
11.17.3 PRODUCT PORTFOLIO
11.17.4 RECENT DEVELOPMENTS

11.18 SOLSYS MEDICAL.

11.18.1 COMPANY OVERVIEW
11.18.2 PRODUCT PORTFOLIO
11.18.3 RECENT DEVELOPMENTS

11.19 VERICEL CORPORATION.

11.19.1 COMPANY OVERVIEW
11.19.2 1.1.2 REVENUE ANALYSIS
11.19.3 PRODUCT PORTFOLIO
11.19.4 RECENT DEVELOPMENTS

11.20 WRIGHT MEDICAL GROUP N.V

11.20.1 COMPANY OVERVIEW
11.20.2 1.1.2 REVENUE ANALYSIS
11.20.3 PRODUCT PORTFOLIO
11.20.4 RECENT DEVELOPMENTS

12 RELATED REPORTS